Windtree Therapeutics Highlights Promising Phase 2b Results for Istaroxime
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) showcased encouraging results from the Phase 2b SEISMiC study of istaroxime, its novel investigational therapy for early cardiogenic shock, at the Technology and …
Windtree Therapeutics Highlights Promising Phase 2b Results for Istaroxime Read More